The challenge is to improve their immune response to malignancy vaccines.
The therapies must keep carefully the balance between activating a effective and safe antitumor immune response and inducing an autoimmune response. Dr Lustgarten concludes: The immune system of the elderly is very different from the young and it is difficult to extrapolate results obtained in the youthful, for use in the old. Our job within the next few years can be to figure out how to robust the previous disease fighting capability by understanding, at a molecular level, its intrinsic defects to properly stimulate antitumor responses. (more…)